---
title: "Testing frequency explains most SDMT differences between natalizumab and rituximab in Swedish MS r"
id: "medrxiv-22-more-tests-higher-scores-testing-frequency-and-sdmt-differences-between"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-22-more-tests-higher-scores-testing-frequency-and-sdmt-differences-between"
content_type: "clinical_feed_article"
specialty: "Neurology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.10.21.26366102v1?rss=1"
published_at: "2026-10-23T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Testing frequency explains most SDMT differences between natalizumab and rituximab in Swedish MS r
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-22-more-tests-higher-scores-testing-frequency-and-sdmt-differences-between
- **Specialty:** [Neurology](https://medichelpline.com/clinical-feed/neurology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.10.21.26366102v1?rss=1)
- **Published At:** 2026-10-23T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The cohort included 2,458 adults with relapsing-remitting multiple sclerosis identified in the **Swedish MS Registry** who initiated either **natalizumab** or **rituximab** between 2010 and 2024 and had at least two on-treatment **SDMT** assessments. - Investigators observed that natalizumab initiators underwent cognitive testing twice as often as rituximab initiators (mean 1.6 vs. 0.8 tests per year), a differential that could produce practice-related score increases. - Mixed-effects models with restricted cubic spline time were used to model SDMT trajectories; the statistical sequence included an adjustment for practice effects using the log of cumulative test number. - Unadjusted model predictions at 3 years showed a natalizumab-minus-rituximab SDMT difference of 7.0 points (95% CI 5.7–8.3); after full adjustment including cumulative tests this fell to 1.6 points (0.7–2.6). - At 1 year the predicted difference moved from 4.4 points (3.3–5.4) unadjusted to −0.3 (−1.2 to 0.6) after full adjustment, indicating attenuation and reversal of the early advantage. - Authors reported that adjusting for cumulative test number substantially attenuated group differences, leaving a small residual effect of uncertain clinical importance; the source did not report additional mechanistic or dosing details. - Ethical oversight was by the Regional Ethical Review Board in Stockholm; data remain available within the registry subject to governance and Swedish data-protection rules.
## Clinical Analysis & Structured Key Points
More tests, higher scores: Testing frequency and SDMT differences between natalizumab and rituximab | medRxiv Skip to main content More tests, higher scores: Testing frequency and SDMT differences between natalizumab and rituximab View ORCID Profile Timothy P Copeland , Sanabel Abdel Hay , View ORCID Profile Fredrik Piehl , View ORCID Profile Katharina Fink , View ORCID Profile Kyla A McKay doi: https://doi.org/10.64898/2026.10.21.26366102 Timothy P Copeland 1 Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Timothy P Copeland For correspondence: copeland.tim{at}gmail.com Sanabel Abdel Hay 1 Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Fredrik Piehl 1 Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Fredrik Piehl Katharina Fink 2 Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Katharina Fink Kyla A McKay 2 Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Kyla A McKay Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract Background: The Symbol Digit Modalities Test (SDMT) measures information processing speed, and repeated testing can increase scores through practice effects. However, how differences in testing frequency bear on comparisons between disease-modifying therapies (DMTs) in real-world cohorts has not been fully explored. Objective: To compare SDMT trajectories between natalizumab and rituximab users and quantify the association of the testing process with those trajectories. Methods: Using the Swedish MS Registry, we studied adults with relapsing-remitting MS initiating natalizumab or rituximab (2010-2024) with >=2 on-treatment SDMT assessments. Mixed-effects models with restricted cubic spline time were sequentially adjusted; log cumulative test number was the practice-effect adjustment. Results: Among 2,458 individuals, natalizumab initiators were tested twice as often as rituximab initiators (1.6 vs. 0.8 tests/year). The predicted natalizumab-minus-rituximab SDMT difference at 3 years was 7.0 points (95% CI 5.7-8.3) unadjusted and 1.6 (0.7-2.6) after full adjustment including cumulative test number; at 1 year it fell from 4.4 (3.3-5.4) to -0.3 (-1.2 to 0.6). Conclusion: Adjustment for cumulative test number substantially attenuated the SDMT difference between natalizumab and rituximab, leaving a small residual difference of uncertain clinical importance and underscoring the need to account for testing frequency in real-world comparisons. Competing Interest Statement TPC and SAH report no competing interests. FP has received research grants from Denka, Janssen, Merck KGaA, Novartis, Pfizer and Sanofi, and fees for serving on data monitoring committees in clinical trials with Lundbeck and Roche, and is supported by the Swedish Research Council (grant no. 2023-02639), the Region Stockholm (grant no. FoUI-987565), the Swedish Brain Fund (grant no. FO2023-0336) and Erling Persson's Foundation (grant no. 2024-0127). KAM receives research funding from the Swedish Research Council and ALF Medicine and has received speaker honoraria from Biogen (2022) and Sanofi-Aventis (2023). KF has served on scientific advisory boards for Alexion, Biogen, Janssen, Merck, Novartis, Takeda and Roche, and has received financial research support from Merck and Amicus. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The Regional Ethical Review Board in Stockholm approved the study (2017/1378-31). Individual informed consent was waived because the study used pseudonymised registry data. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability Data are held within the Swedish MS Registry and are available to qualified researchers subject to registry governance and Swedish data-protection legislation. Funder Information Declared Swedish Research Council , 2023-02567 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Back to top Previous Next Posted October 23, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following More tests, higher scores: Testing frequency and SDMT differences between natalizumab and rituximab Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share More tests, higher scores: Testing frequency and SDMT differences between natalizumab and rituximab Timothy P Copeland , Sanabel Abdel Hay , Fredrik Piehl , Katharina Fink , Kyla A McKay medRxiv 2026.10.21.26366102; doi: https://doi.org/10.64898/2026.10.21.26366102 Share This Article: Copy Citation Tools More tests, higher scores: Testing frequency and SDMT differences between natalizumab and rituximab Timothy P Copeland , Sanabel Abdel Hay , Fredrik Piehl , Katharina Fink , Kyla A McKay medRxiv 2026.10.21.26366102; doi: https://doi.org/10.64898/2026.10.21.26366102 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (633) Allergy and Immunology (914) Anesthesia (345) Cardiovascular Medicine (4943) Dentistry and Oral Medicine (490) Dermatology (425) Emergency Medicine (671) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1667) Epidemiology (16161) Forensic Medicine (35) Gastroenterology (1236) Genetic and Genomic Medicine (7209) Geriatric Medicine (747) Health Economics (1091) Health Informatics (5222) Health Policy (1456) Health Systems and Quality Improvement (1812) Hematology (597) HIV/AIDS (1370) Infectious Diseases (except HIV/AIDS) (16426) Intensive Care and Critical Care Medicine (1192) Medical Education (690) Medical Ethics (156) Nephrology (739) Neurology (7497) Nursing (375) Nutrition (1114) Obstetrics and Gynecology (1281) Occupational and Environmental Health (1031) Oncology (3708) Ophthalmology (1079) Orthopedics (401) Otolaryngology (462) Pain Medicine (493) Palliative Medicine (142) Pathology (717) Pediatrics (1844) Pharmacology and Therapeutics (749) Primary Care Research (781) Psychiatry and Clinical Psychology (6065) Public and Global Health (9915) Radiology and Imaging (2499) Rehabilitation Medicine and Physical Therapy (1499) Respiratory Medicine (1263) Rheumatology (655) Sexual and Reproductive Health (794) Sports Medicine (594) Surgery (795) Toxicology (109) Transplantation (315) Urology (303)
## Related Clinical Research

- [Nonmedical Switch from MabThera to Truxima Rituximab in Multiple Sclerosis: Effectiveness and Tole](https://medichelpline.com/clinical-feed/medrxiv-21-effectiveness-and-tolerability-of-nonmedical-switching-from-originator-mabthera.md)
- [EBV reactivation primes peripheral immune changes before multiple sclerosis relapse](https://medichelpline.com/clinical-feed/nature-0-ebv-reactivation-priming-of-the-peripheral-immune-system-in-multiple-sclerosis.md)
- [Disease-modifying therapies linked to better olfactory function via NK cell–microbiota interaction](https://medichelpline.com/clinical-feed/frontiers-in-immunology-16-disease-modifying-therapies-are-associated-with-improved-olfactory-function-via.md)
- [Concurrent Neurofibromatosis Type 1 and Multiple Sclerosis in a Child: MRI, CSF, and 2024 Criteria](https://medichelpline.com/clinical-feed/pubmed-42485588.md) (DOI: 10.1212/WNL.0000000000218240)
- [Rituximab in Autoimmune Myasthenic Syndromes: Real‑World Outcomes in MG and LEMS](https://medichelpline.com/clinical-feed/medrxiv-12-rituximab-for-autoimmune-myasthenic-syndromes-a-retrospective-cohort-study-in.md)

## Navigation
- [← Back to Neurology Feed](https://medichelpline.com/clinical-feed/neurology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.